Nonpeptide factor Xa inhibitors III: Effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 3, 2002, Pages 993-1000

  Wong, Pancras C ^a   Crain, Earl J ^a   Watson, Carol A ^a   Zaspel, Alverna M ^a   Wright, Matthew R ^a,b   Lam, Patrick Y ^a   Pinto, Donald J P ^a   Wexler, Ruth R ^a   Knabb, Robert M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (AMINOMETHYL)PHENYL] N [3 FLUORO 2' (METHYLSULFONYL)(1,1' BIPHENYL) 4 YL] 3 (TRIFLUOROMETHYL) 1H PYRAZOLE 5 CARBOXAMIDE; 1 [3 (AMINOMETHYL)PHENYL] N [3 FLUORO 2' (METHYLSULFONYL)[1,1' BIPHENYL] 4 YL] 3 (TRIFLUOROMETHYL) 1H PYRAZOLE 5 CARBOXAMIDE; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DRUG VEHICLE; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PEPTIDE; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY INJURY; ARTICLE; BLEEDING; BLEEDING TIME; CAROTID ARTERY FLOW; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MODEL; DOSE CALCULATION; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; HEMOSTASIS; NONHUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; RABBIT; THROMBOPLASTIN TIME; TIME;

ADMINISTRATION, ORAL; ANIMALS; ANTITHROMBIN III; ASPIRIN; BLEEDING TIME; BLOOD FLOW VELOCITY; CAROTID ARTERIES; CAROTID ARTERY THROMBOSIS; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; MALE; PARTIAL THROMBOPLASTIN TIME; PLATELET AGGREGATION; PYRAZOLES; RABBITS; REGIONAL BLOOD FLOW; SULFONES; THROMBIN TIME;

EID: 0036897444     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.040089     Document Type: Article

References (35)

1. Abendschein DR, Baum PK, Martin DJ, Vergona R, Post J, Rumennik G, Sullivan ME, Eisenberg PR, and Light DR (2000) Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits. J Cardiovasc Pharmacol 35:796-805.
2. Awtry EH and Loscalzo J (2000) Aspirin. Circulation 101:1206-1218.
3. Barrett JS, Davidson AF, Jiao QT, Mosqueda-Garcia R, Kornhauser DM, Gangrade NK, Jona JA, and Pieniaszek HJ Jr (2001) The effect of food, formulation and dosing duration on the pharmacokinetics of DPC423, a potent factor Xa inhibitor. J Clin Pharmacol 41:1023.
4. Bossavy J-P, Sakariassen KS, Thalamas C, Boneu B, and Cadroy Y (1999) Antithrombotic efficacy of the vitamin K antagonist fluindione in a human ex vivo model of arterial thrombosis. Effect of anticoagulation level and combination therapy with aspirin. Arterioscler Thromb Vasc Biol 19:2269-2275.
5. Cody RP and Smith JK (1991) Applied Statistics and the SAS Programming Language, 3rd ed, pp 98-202, Prentice Hall, Englewood Cliffs, New Jersey.
6. Davie EW, Fujikawa K, and Kisiel W (1991) The coagulation cascade: Initiation, maintenance and regulation. Biochemistry 30:10363-10370.
7. Dyke CK, Becker RC, Kleiman NS, Hochman JS, Bovill EG, Lincoff M, Gerstenblith G, Dzavik V, Gardner LH, Hasselblad V, et al. (2002) First experience with direct factor Xa inhibition in patients with stable coronary disease. A pharmacokinetic and pharmacodynamic evaluation. Circulation 105:2382-2388.
8. Feuerstein GZ, Patel A, Toomey JR, Bugelski P, Nichols AJ, Church WR, Valocik R, Koster P, Baker A, and Blackburn MN (1999) Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. Arterioscler Thromb Vasc Biol 19:2554-2562.
9. Giles AR, Tinlin S, and Greenwood R (1982) A canine model of hemophilic (factor VIII:C deficiency) bleeding. Blood 60:727-730.
10. Hara T, Yokoyama A, Morishima Y, and Kunitada S (1995) Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb Res 80:99-104.
11. Hauptmann J and Stürzebecher J (1999) Synthetic inhibitors of thrombin and factor Xa: From bench to bedside. Thromb Res 93:203-241.
12. Herbert JM, Bernat A, Dol F, Hérault JP, Crépon B, and Lormeau JC (1996a) DX 9065A, a novel, synthetic, selective and orally active inhibitor of factor Xa: In vitro and in vivo studies. J Pharmacol Exp Ther 276:1030-1038.
13. Herbert J-M, Dol F, Bernat A, Falotico R, Lalé A, and Savi P (1998) The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost 80:512-518.
14. Herbert JM, Hérault JP, Bernat A, van Amsterdam RGM, Vogel GMT, Lormeau JC, Petitou M, and Meuleman DG (1996b) Biochemical and pharmacological properties of SANORG 32701. Comparison with "synthetic pentasaccharide" (SR 90107/ ORG 31540) and standard heparin. Circ Res 79:590-600.
15. Himber J, Kirchhofer D, Riederer M, Tschopp TB, Steiner B, and Roux SP (1997) Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemost 78:1142-1149.
16. Hollenbach S, Sinha U, Lin P-H, Needham K, Frey L, Hancock T, Wong A, and Wolf D (1994) A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis. Thromb Haemost 71:357-362.
17. Kawasaki T, Sato K, Sakai Y, Hirayama F, Koshio H, Taniuchi Y, and Matsumoto Y (1998) Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis. Thromb Haemost 79:410-416.
18. Kettner C, Mersinger L, and Knabb R (1990) The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem 265:18289-97.
19. Leadley RJ Jr (2001) Coagulation factor Xa inhibition: biological background and rationale. Curr Topics Med Chem 1:151-159.
20. McClanahan TB, Hicks GW, Morrison AL, Peng Y-W, Janiczek-Dolphin N, Mertz TE, Sullivan ME, Morser J, Juneau PL, and Leadley RL (2001) The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis. Eur J Pharmacol 432:187-194.
21. McKeage K and Plosker GL (2001) Argatroban. Drugs 61:515-522.
22. Morishima Y, Tanabe K, Terada Y, Hara T, and Kunitada (1997) Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: Comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost 78:1366-1371.
23. Noble S and Spencer CM (1998) Enoxaparin: A review of its clinical potential in the management of coronary artery disease. Drugs 56:259-272.
24. Pinto DJ, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E, Cacciola J, Rossi KA, Alexander RS, Smallwood AM, Luettgen JM, et al. (2001) The discovery of 1-[3- (aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)[1, 1′-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide, a highly potent, selective and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 44:566-578.
25. Quan ML and Wexler RR (2001) The design and synthesis of noncovalent factor Xa inhibitors. Curr Topics Med Chem 1:137-149.
26. Refino CJ, Jeet S, DeGuzman L, Bunting S, and Kirchhofer D (2002) A human antibody that inhibits factor IX/IXa function potently inhibits arterial thrombosis without increasing bleeding. Arterioscler Thromb Vasc Biol 22:517-522.
27. Sato K, Kawasaki T, Taniuchi Y, Hirayama F, Koshio H, and Matsumoto Y (1997) YM-60828, a novel factor Xa inhibitor: Separation of its antithrombotic effects from its prolongation of bleeding time. Eur J Pharmacol 339:141-146.
28. Sato K, Taniuchi Y, Kawasaki T, Hirayama F, Koshio H, and Matsumoto Y (1998) Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor and coagulation parameters in rats. Eur J Pharmacol 347:231-236.
29. Schumacher WA, Steinbacher TE, Heran CL, Megill JR, and Durham SK (1993) Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis. Thromb Haemost 9:509-514.
30. Sinha U, Ku P, Malinowski J, Zhu BY, Scarborough RM, Marlowe CK, Wong PW, Lin PH, and Hollenbach SJ (2000) Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis. Eur J Pharmacol 395:51-56.
31. Szczeklik A, Krzanowski M, Gora P, and Radwan J (1992) Antiplatelet drugs and generation of thrombin in clotting blood. Blood 80:2006-2011.
32. Taniuchi Y, Sakai Y, Hisamichi N, Kayama M, Mano Y, Sato K, Hirayama F, Koshio H, Matsumoto Y, and Kawasaki T (1998) Biochemical and pharmacological characterization of YM-60828, a newly synthetized and orally active inhibitor of human factor Xa. Thromb Haemost 79:543-548.
33. Wong PC, Crain EJ, Knabb RM, Meade RP, Quan ML, Watson CA, Wexler RR, Wright MR, and Slee AM (2000a) Nonpeptide factor Xa inhibitors: II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis. J Pharmacol Exp Ther 295:212-218.
34. Wong PC, Pinto DJP, and Knabb RM (2002) Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. Cardiovasc Drug Rev 20:137-152.
35. Wong PC, Quan ML, Crain EJ, Watson CA, Wexler RR, and Knabb RM (2000b) Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. J Pharmacol Exp Ther 292:351-357.